secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001157523-23-000741
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q1 2023 LIVMARLI sales $29.1M, up 167% YoY; closed $316M convertible note
-------------------------------------------------------------------------------

- Net product sales for LIVMARLI $29.1M in Q1 2023 vs $10.9M in Q1 2022, a 167% increase.
- Total revenue $31.6M; operating expenses $58.7M; cash $232.1M as of March 31, 2023.
- FDA approved label expansion for LIVMARLI to include infants 3 months+ in Alagille syndrome.
- sNDA for LIVMARLI in PFIC accepted with PDUFA date December 13, 2023.
- Closed $316.3M upsized convertible notes offering at 4.00% due 2029; repurchased 9.75% royalty obligation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000115752323000741/0001157523-23-000741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000115752323000741/a53394174.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-000741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer